-transparent.png){kind=logo}
Pharmacokinetic profiles of imipramine and a newer tetracyclic antidepressant, maprotiline, were studied in elderly (75-83 years of age) subjects who were given a single oral dose of 125 and 175 mg, respectively, of these drugs. The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg). Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine. It appears that the elimination half-life of imipramine is longer and its plasma clearance is markedly reduced in elderly subjects when compared to values reported in young adults. Subjective clinical side effects were minimal with the two drugs. However, alterations in heart rate, blood pressure, or electrocardiogram occurred in all subjects. This suggests that caution should be exercised before initiating and during the treatment of elderly patients with these antidepressant drugs.
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
January 1977,
Archives internationales de pharmacodynamie et de therapie,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
March 1982,
The Journal of clinical psychiatry,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
August 1997,
British journal of clinical pharmacology,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
January 1988,
European journal of clinical pharmacology,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
August 1998,
Pharmaceutical research,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
January 1998,
Drugs under experimental and clinical research,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
January 1985,
European journal of rheumatology and inflammation,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
August 1985,
British journal of clinical pharmacology,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
November 1993,
British journal of clinical pharmacology,
P D Hrdina, and
V Rovei, and
J F Henry, and
M P Hervy, and
R Gomeni, and
F Forette, and
P L Morselli
January 1988,
International journal of clinical pharmacology research,
